Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)-Reference-Cited by-同舟云学术

Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)

Published:2018-04-19 Issue:1 Volume:104 Page:69-83
ISSN:0741-5400
Container-title:Journal of Leukocyte Biology
language:en
Short-container-title:J Leukoc Biol

Author:

Khoury Paneez¹,Akuthota Praveen²,Ackerman Steven J.³,Arron Joseph R.⁴,Bochner Bruce S.⁵^ORCID,Collins Margaret H.⁶,Kahn Jean-Emmanuel⁷,Fulkerson Patricia C.⁸,Gleich Gerald J.⁹,Gopal-Srivastava Rashmi¹⁰,Jacobsen Elizabeth A.¹¹,Leiferman Kristen M.¹²,Francesca Levi-Schaffer¹³,Mathur Sameer K.¹⁴,Minnicozzi Michael¹⁵,Prussin Calman¹⁶,Rothenberg Marc E.⁸,Roufosse Florence¹⁷,Sable Kathleen¹⁸,Simon Dagmar¹⁹,Simon Hans-Uwe²⁰,Spencer Lisa A.²¹,Steinfeld Jonathan²²,Wardlaw Andrew J.²³,Wechsler Michael E.²⁴,Weller Peter F.²¹,Klion Amy D.¹

Affiliation:

1. Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda Maryland USA

2. Division of Pulmonary, Critical Care and Sleep Medicine; University of California; La Jolla California USA

3. Department of Biochemistry and Molecular Genetics; University of Illinois at Chicago; Chicago Illinois USA

4. Immunology Discovery; Genentech, Inc.; South San Francisco California USA

5. Department of Medicine, Division of Allergy and Immunology; Northwestern University Feinberg School of Medicine; Chicago Illinois USA

6. Division of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center; University of Cincinnati; Cincinnati Ohio USA

7. Department of Internal Medicine; Hôpital Foch; Suresnes France

8. Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics; University of Cincinnati College of Medicine; Cincinnati Ohio USA

9. Departments of Dermatology and Medicine; University of Utah Health; Salt Lake City Utah USA

10. National Center for Advancing Translational Sciences; National Institutes of Health; Bethesda Maryland USA

11. Mayo Clinic Arizona; Scottsdale Arizona USA

12. Department of Dermatology; University of Utah Health; Salt Lake City Utah USA

13. Pharmacology and Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine; The Hebrew University; Jerusalem Israel

14. University of Wisconsin School of Medicine and Public Health; Madison Wisconsin USA

15. Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda Maryland USA

16. Knopp Biosciences; Pittsburgh Pennsylvania USA

17. Hôpital Erasme; Université Libre de Bruxelles; Brussels Belgium

18. American Partnership For Eosinophilic Disorders; Atlanta Georgia USA

19. Department of Dermatology, Bern University Hospital; University of Bern; Bern Switzerland

20. Institute of Pharmacology; University of Bern; Bern Switzerland

21. Beth Israel Deaconess Medical Center; Harvard Medical School; Boston Massachusetts USA

22. GlaxoSmithKline; Philadelphia Pennsylvania USA

23. Institute for Lung Health; University of Leicester; Leicester England

24. National Jewish Health; Denver Colorado USA

Funder

National Institutes of Health

U.S. Food and Drug Administration

American Partnership for Eosinophilic Disorders

Campaign Urging Research for Eosinophilic Disease

Buckeye Career Center Foundation

Sunshine Charitable Foundation

Rare Disease Clinical Research Network

National Fund for Scientific Research

Israel Science Foundation

National Institute for Health Research

National Institute of Allergy and Infectious Diseases

Publisher

Wiley

Subject

Cell Biology,Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/JLB.5MR0118-028R/fullpdf

Reference135 articles.

1. Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD);Bochner;J Allergy Clin Immunol,2012

2. Inter- and intraobserver reliability and validation of a new method for determination of eosinophil counts in patients with esophageal eosinophilia;Dellon;Dig Dis Sci,2010

3. Value of an additional review for eosinophil quantification in esophageal biopsies;Stucke;J Pediatr Gastroenterol Nutr,2015

4. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring;Collins;Dis Esophagus,2017

5. A novel histologic scoring system to evaluate mucosal biopsies from patients with eosinophilic esophagitis;Protheroe;Clin Gastroenterol Hepatol,2009

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sputum eosinophil peroxidase: Building a better biomarker for eosinophilic asthma;Journal of Allergy and Clinical Immunology;2024-09

2. Utility of eosinophil peroxidase as a biomarker of eosinophilic inflammation in asthma;Journal of Allergy and Clinical Immunology;2024-09

3. Pathophysiology of hypereosinophilia-associated heart disease;2024-07-05

4. Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities;Journal of Leukocyte Biology;2024-03-08

5. Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics;ERJ Open Research;2023-11-09